Induced Pluripotent Stem Cells Production Market Insights Reveal Key Trends and Innovations

The global induced pluripotent stem cells production market size is expected to reach USD 2.76 billion by 2030, registering a CAGR of 9.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market. Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth. In addition, the prevalence of chronic disorders is also driving the growth of the induced pluripotent stem cells production market, as conditions like heart disease, stroke, diabetes, and many more can be treated by utilizing iPSCs-mediated therapy. For example, according to the International Diabetes Federation (IDF), 537 million people are already living with diabetes in 2021.

The rising research activities during COVID-19 pandemic have positively impacted the market. The pandemic fueled research in many fields as the SARS CoV-2 infection resulted in many diseases in the patients. For instance, in April 2021, researchers from USA stated that up to 25% of COVID-19 patients suffered cardiac dysfunction. Through their research article, they demonstrated the pathogenesis via exposure of iPSCs-derived cardiac cells to SARS CoV-2, and similar alterations were confirmed from human autopsy specimens of the patients. Such insights allow the use of induced pluripotent stem cells (iPSCs) as drug or therapy development platforms and their utilization in the management of the long-term effects of COVID-19.

Gather more insights about the market drivers, restrains and growth of the Global Induced Pluripotent Stem Cells Production Market

Induced pluripotent stem cells are cells that are derived from adult somatic cells and then further reprogrammed to obtain the pluripotency as that of ESCs. These iPSCs are proving to be an ethically uncomplicated alternative for research that involves ESCs. The derivation of the ESCs is associated with the destruction of an embryo at the blastocyte stage, which has led to a maximum number of ethical debates. However, induced pluripotent stem cells have solved the ethical issue over the destruction of human embryos in research by involving only the genetic reprogramming of somatic cells. This has propelled the market growth and resulted in numerous applications including drug discovery, disease modeling, toxicology testing, and many others. For instance, in August 2021, Fate Therapeutics announced the treatment of the first patient with FT819 during clinical trials. FT819 is an engineered CAR-T cell therapy that is derived from iPSCs. Also, the rising focus of the research community on exploring applications of induced pluripotent stem cells in regenerative medicine due to their unique characteristics such as differential potential, self-renewable, immunomodulatory properties, and others; is set to drive the market expansion.

Induced Pluripotent Stem Cells Production Market Report Highlights

• By process, the manual iPSC production process segment dominated the market and accounted for the largest revenue share in 2023.

• By workflow, the cell culture segment dominated the market with the largest revenue share of 37.34% in 2023. Cell culture workflow is inclusive of revenues generated from iPSC harvest products, expansion products, and differentiation products; thus contributing to the market relevance of this segment.

• By product, the consumables and kits segment dominated the market and accounted for the largest revenue share of 40.32% in 2023. The never-ceasing research and development activities in the iPSCs space are driving the demand for various consumables & kits.

• By application, drug development & discovery segment dominated the market with the largest revenue share of 43.33% in 2023.

• By end-user, the biotechnology and pharmaceutical companies segment dominated the market with the largest revenue share of 59.35% in 2023. The availability and adoption of various kits, consumables, and instruments along with iPSCs products are driving the revenue generation in this segment.

• North America dominated the market and accounted for the largest revenue share of 40.98% in 2023. The growing incidence of chronic diseases in this region, developed healthcare infrastructure, funds from private & government initiatives, and strategic business models are driving the revenue generation in the marketspace.

List of Key Players in Induced Pluripotent Stem Cells Production Market

• Lonza
• Axol Bioscience Ltd.
• Evotec
• Hitachi, Ltd.
• REPROCELL Inc.
• Merck KGaA
• REPROCELLS, Inc.
• Fate Therapeutics
• Thermo Fisher Scientific, Inc.
• StemCellsFactory III
• Applied StemCells, Inc.

Order a free sample PDF of the Induced Pluripotent Stem Cells Production Market Intelligence Study, published by Grand View Research.